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Abstract
Background: Attendance rates of cervical screening programs can be increased by offering HPV self-sampling to
non-attendees. Acceptability, DNA yield, lavage volumes and choice of hrHPV test can influence effectiveness of the
self-sampling procedures and could therefore play a role in recruiting non-attendees. To increase user-friendliness, a
frequently used lavage sampler was modified. In this study, we compared this second generation lavage device
with the first generation device within similar birth cohorts.
Methods: Within a large self-sampling cohort-study among non-responders of the Dutch cervical screening
program, a subset of 2,644 women received a second generation self-sampling lavage device, while 11,977 women,
matched for age and ZIP-code, received the first generation model. The second generation device was different in
shape, color, lavage volume, and packaging, in comparison to its first generation model. The Cochran’s test was
used to compare both devices for hrHPV positivity rate and response rate. To correct for possible heterogeneity
between age and ZIP codes in both groups the Breslow-Day test of homogeneity was used. A T-test was utilized to
compare DNA yields of the obtained material in both groups.
Results: Median DNA yields were 90.4 μg/ml (95% CI 83.2-97.5) and 91.1 μg/ml (95% CI 77.8-104.4, p= 0.726) and
hrHPV positivity rates were 8.2% and 6.9% (p= 0.419) per sample self-collected by the second - and the first
generation of the device (p= 0.726), respectively. In addition, response rates were comparable for the two models
(35.4% versus 34.4%, p= 0.654).
Conclusions: Replacing the first generation self-sampling device by an ergonomically improved, second generation
device resulted in equal DNA yields, comparable hrHPV positivity rates and similar response rates. Therefore, it can
be concluded that the clinical performance of the first and second generation models are similar. Moreover,
participation of non-attendees in cervical cancer screening is probably not predominantly determined by the type
of self-collection device.
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Background
In developed countries, incidence rate of and mortality
from cervical cancer have decreased since the introduc-
tion of cytology based cervical screening [1-4]. However,
randomized controlled trials have shown that high-risk
human papillomavirus (hrHPV) testing provides a super-
ior protection against high-grade cervical intraepithelial
neoplasia than cytology [5-7]. Therefore, population based
screening could be improved by the introduction of pri-
mary hrHPV testing. However, this will not affect the par-
ticipation rate of programmed cervical screening, which
often is suboptimal. Since non-attendance is associated
with an increased risk of developing cervical cancer, it is
especially important to reach these non-attending women
[1,8,9]. Recent studies have shown that offering self-
collection devices for hrHPV testing on cervico-vaginal
specimens to non-attendees may improve compliance to
screening [10-17]. Additionally, self-sampling has facilita-
ted access to cervical screening for women in developing
countries [18-20].
Meta-analyses and systematic reviews have shown a high
level of concordance in HPV detection rates between self-
sampled specimens and clinician-collected samples [21-24].
Moreover, some studies have reported a similar sensitivity
between the two sampling methods with respect to detec-
tion of high-grade cervical intraepithelial neoplasia or
worse (CIN2+), but data are inconsistent [21-23,25-27].
The variations in clinical performance might be explained
by the use of different HPV assays in combination with
various self-sampling devices (e.g., brushes, swabs, tam-
pons and lavage devices) [27]. Nevertheless, offering a
self-sampling device seems a good method to increase cer-
vical screening coverage [11].
An example of a frequently used self-collection
method which can rinse the upper vagina and cervix to
obtain cervico-vaginal material is the Delphi lavage deviceW
(Delphi Bioscience BV, Scherpenzeel, The Netherlands).
Brink et al. [25] validated the first generation of this device
by showing that its use, in combination with hrHPV testing
by GP5+/6+ PCR, resulted in a similar detection rate of
CIN2+ lesions compared to physician sampling of cervical
material. This device has successfully been used in studies
with women who did not respond to an invitation of the
regular cervical screening program [11,13,14].
Yet, based on spontaneous and actively requested feed-
back from more than 10,000 study-participants as well as
market research, a modification of this lavage sampler
(‘second generation’) was introduced in order to increase
user-friendliness (see Methods section for the alterations).
A questionnaire-based Dutch study scoring for first im-
pression, showed higher scores for the second generation
device (n=155) when compared to scores of women in a
separate study using the first generation device (unpub-
lished data). A user questionnaire study on the use of the
second generation device (n=50) showed a high accept-
ability and user-friendliness (measured for ease of its use,
ease to follow instructions, comfort level, recommen-
dability and preferability of device for the next screening)
comparable to the New York study among 197 women
[28,29]. So the second generation device showed an im-
proved first impression compared to the first generation
and a negligible effect on user acceptability which was
already high.
This study compares clinical performance of the second
generation model of a self-sampling device (Figure 1b) to
the first generation model (Figure 1a) by comparing the
hrHPV positivity rate, acquired DNA yields and participa-
tion rate.
Methods
Study population
Our validation study was conducted within a large study
among non-attendees of the screening program in the
year 2007, which were offered self-sampling between
October 2010 and June 2011. This trial was approved by
the national ethics committee (Ministry of Public Health
No 2010/04WBO) and informed consent was given by all
participating women. From this large study we excluded
women whose age and ZIP-code combination was not ob-
served in both subgroups (of women who received the
second generation sampler). In total, we retained 2,644
women who had received the second generation sampler
a b
Figure 1 Design of the Delphi Screener. a: First generation of the device b: Second generation of the device.
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and 11,977 women who had received the first generation
of the device. All participants received a self-sampling kit
at their home address with a collection device, a collection
tube, an explanatory letter, an informed consent form,
user instructions and a return envelope. Women were
asked to return the collection tube containing the cervico-
vaginal lavage specimen and the signed informed consent
form in a return-envelope to the laboratory of the VU
University Medical Center for hrHPV testing. In both
groups, self-sampling kits contained similar content ex-
cept for the version of the lavage device and the accom-
panying user instructions.
Sampling
The first generation sampler is a plastic, syringe-like de-
vice and is provided in a blister. The sampler is pre-
filled with 5 ml sterile saline. The handgrip, as well as
the insertion part are white colored and the diameter of
the insertion part is 1.8 cm. The top of the insertion part
is covered with a red silicone cap that prevents the fluid
from leaking and prevents accidental use of the plunger.
Once the cap is removed, the plunger can be pushed
(See Additional file 1 for user instructions of the first
generation device).
The second generation sampler is a plastic device pro-
vided in a pouch. The sampler is pre-filled with 3 ml ste-
rile saline, which reduces the risk to leak lavage fluid during
sample collection compared to the first generation. The in-
sertion part itself did not change in length, as 12 cm is ne-
cessary to reach the cervix in the majority of women.
However, the insertion part of the second generation de-
vice is distinguished from the handgrip by color (white
and blue respectively). The diameter of the insertion part
is 1.6 cm; therefore, this new model is leaner than the first
generation. The top of the insertion part is covered with a
seal to prevent leakage and accidental use and is easier to
remove than the cap of the first generation device. Instead
of a syringe-like mechanism for which the thumb is
needed to push the plunger, the second generation is
designed to improve both the grip and strength to push
the plunger. Moreover, the new design can be used in lay-
ing down as well as in sitting position. See Additional file
2 for user instructions of the second generation device.
HPV testing
The self-sampled material was tested for hrHPV in two
different laboratories, respectively the department of
Pathology, VU University Medical Center (VUmc),
Amsterdam, the Netherlands and the department of
Medical Microbiology, Radboud University Nijmegen
Medical Centre (RUNMC), Nijmegen, the Netherlands.
Upon arrival of the self-sampled material in the labo-
ratory, tubes were centrifuged to concentrate the cell
material from the lavage specimens. Subsequently, the
supernatant was removed and the pellet was resuspended
in 1.5 ml ThinPrep preservation medium (Hologic). The
Hamilton MICROLAB STARlet robot (VUmc) and the
Roche MagNA Pure LC Isolation station (Roche Diagnos-
tics) (RUNMC) were used to isolate DNA from 1/10th of
this material. The hrHPV test was performed on the iso-
lated material by the GP 5+/6+ PCR-EIA, as described
previously [30]. Furthermore, for quality control for the
presence of DNA and the absence of PCR inhibitors in
the isolated material, a PCR for the B-globin gene was
performed on the isolated material of those samples that
had a visually small pellet at arrival in the lab, and on an-
other random 11% of the samples. In case of hrHPV posi-
tive material, DNA yield (which is a proxy for the cell
yield) was estimated by measuring DNA concentrations
(ng/μl) in 1 μl DNA extract using the NanoDrop (Thermo
Scientific) according to recommendations of the manufac-
turer. This value was subsequently used to calculate the
DNA yield (μg/mL) in self-sampled material.
Statistical analysis
To test whether the hrHPV positivity and participation
rate differed between a first and second generation device,
women were stratified according to ZIP code and age
(5 year cohorts). Strata without data for both the first and
second generation device were discarded. Note that the
hrHPV positivity and participation rate have different
denominators and hence the number of strata may be dif-
ferent for the hrHPV positivity and participation rate ana-
lyses. To check for possible heterogeneity between age
and ZIP codes, the Breslow-Day test of homogeneity was
used. Within strata, differences between the first and se-
cond generation devices were tested by Mantel Haenszel
Cochran’s test. A T-test was utilized to compare DNA
yields of the obtained material in both groups. A logistic
regression was performed to estimate the effects of age on
response rate, separately for the first and second genera-
tion of lavage device.
Results
Characteristics of trial cohort
The flowchart of the study is shown in Figure 2. The
total study group involved 14,621 women between 33
and 63 years old (median age of 43.4 years) of whom
2,644 women (18.1%) received the second generation of
the device and 11,977 (81.9%) ZIP code and age-matched
women received the first generation.
HrHPV detection rate
Of all 14,621 invited women, 5,057 participated by
returning their material to our laboratory for hrHPV test-
ing. For our comparison of the hrHPV detection rate,
2,871 women were taken into account of whom the age
and ZIP-codes matched between both subgroups. Five
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women were excluded because of an invalid hrHPV test
due to a negative result of the quality control; the results
of this quality control are described in the next paragraph.
Thus, in total, the self-samples of 2,866 women were
taken into account to calculate and compare the hrHPV
positivity rates. Of the 803 participants in the second gen-
eration group who submitted a self-sampled specimen, 66
women (8.2%) were tested hrHPV positive (Table 1), while
the first generation group included 143 (6.9%) hrHPV
positive women. The hrHPV positivity rate was not signifi-
cantly different between the two generations (OR 1.123,
95% CI 0.813-1.552, p= 0.419).
Quality control
A random quality control, consisting of a random B-
globin PCR, as performed on 315 of the 2,871 samples,
ZIP-code and age matched women
N= 14,621
First generation
device
N= 11,977
Second generation 
device
N= 2,644
Response rate
N= 4,121
(34.4%)
Response rate
N= 936
(35.4%)
Total hrHPV test results
N= 5,057
hrHPV test results
ZIP-code and 
age matched
N= 2,871 HPV NTD
N= 5
Exclusion:
Results not ZIP-code 
and age matched
N= 2,186
First generation device
N= 2,063
66% analyzed in Vumc
34% analyzed in RUNMC
Second generation device
N= 803
72% analyzed in Vumc
28% analyzed in RUNMC
hrHPV positive
N= 143
(6.9%)
hrHPV positive
N= 66
(8.2%)
hrHPV negative
N= 1,920
(93.1%)
hrHPV negative
N= 737
(91.8%)
Figure 2 Study design.
Table 1 hrHPV positivity rate of the second generation of the device versus the first generation
hrHPV test result
hrHPV negative hrHPV positivea
Type of Screener First generation 1,920 (93.1%) 143 (6.9%)
(control)
Second generation 737 (91.8%) 66 (8.2%)
(case)
Total 2,657 (92.7%) 209 (7.3%)
a p= 0.419 (Cochran’s test).
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has revealed that there is no difference between the assay
performance on the first compared to the second gene-
ration device. Two out of 234 samples (0.9%) collected by
the first generation device had a negative B-globin result.
None of the 81 samples obtained with the second gener-
ation device were B-globin negative. In addition to the
random quality control, we performed a quality control
on all samples with a visually small pellet by arrival in our
laboratory (n=56). Of the 33 samples with a visually small
pellet that were collected by the first generation of the de-
vice, one sample (3.0%) had a negative B-globin test. In
samples collected by the second generation device, two of
the 23 checked samples (8.7%) were B-globin negative.
The five samples with a negative B-globin test were scored
as ‘invalid HPV test result’ because of insufficient material,
while all samples with a positive B-globin test were scored
as ‘sufficient material’ and were taken into account for fur-
ther analysis with regard to the hrHPV detection rate as
described above.
DNA yield
DNA yields were measured in all hrHPV positive samples
of the total participants’ cohort of 5,057 women (Figure 2).
These samples comprised 81 samples collected with the
second generation of the device and 295 with the first gen-
eration. The mean DNA yield (μg) per ml sampled material
with the new version was 91.1 μg/ml (95% CI 77.8-104.4),
and that of material sampled with the earlier version was
90.4 μg/ml (95% CI 83.2-97.5) per sample (Table 2). The
T-test was used to compare these DNA yields. The distri-
bution of the lnDNA concentrations was confirmed to be
normal. The T-test showed that an equal DNA yield was
obtained with both self-sampling devices (p= 0.726). The
mean difference between the two sampling methods was
1.039 (95% CI 0.173-1.286).
Participation rate
Table 3 shows the participation rate of all women in the
study. In the group of women who received the second
generation, 936 of the 2,644 invited women (35.4%)
participated by sending their self-sampled specimen to the
laboratory. In the cohort that received the earlier version,
4,121 of the 11,977 women (34.4%) returned their self-
sampled material. Taken together, a similar participa-
tion rate was observed (OR 1.020, 95% CI 0.930-1.118,
p= 0.654). In Table 4, all invited women were grouped into
seven age cohorts to measure response rate for each age
group. In none of the age groups there was a difference in
response rate in women who received the first generation
device compared to those who received the second gener-
ation (i.e., all Pearson chi-square p values were >0.05).
Furthermore, a logistic regression analysis was performed
to measure whether the response rate was associated with
age. This analysis showed no effect of age neither for the
first nor for the second generation device. Odds ratios
were 0.982 (95% CI 0.960-1.004, p= 0.112) and 0.992 (95%
CI 0.948-1.039, p= 0.745), respectively.
Discussion
Our data show that both the hrHPV positivity rate and
the DNA yield of the second generation of the Delphi
screener were equal to those of the validated, first gener-
ation of this device. With regard to the hrHPV positivity
Table 2 Comparison of DNA concentration of the second
generation versus the first generation in hrHPV positive
samples
DNA yield in μg per ml
self-sampled material
First generation
(n=295)
Second generation
(n=81)
Meana 90.4 91.1
(95% CI 83.2-97.5) (95% CI 77.8-104.4)
Median 79.4 79.7
Minimum 1.0 3.1
Maximum 391.2 256.5
a p= 0.726 (T-test).
Table 3 Participation rates in women receiving the
second generation and the first generation of the device
Response rate
No response Responsea
Type of Screener First generation 7,856 (65.6%) 4,121 (34.4%)
(control)
Second generation 1,708 (64.6%) 936 (35.4%)
(case)
Total 9,564 (65.4%) 5,057 (34.6%)
a p= 0.654 (Cochran’s test).
Table 4 Comparison of participation rates by age group
in women receiving the second generation and the first
generation of the device
Response rate
Age group
(in years)
First generation
device
Second generation
device
n % n % p-valuea
60-64 71 25.9% 26 33.8% 0.173
55-59 330 32.0% 85 32.4% 0.901
50-54 519 35.8% 141 38.6% 0.323
45-49 564 34.1% 122 32.0% 0.435
40-44 706 34.3% 169 37.1% 0.250
35-39 1,085 36.3% 213 36.8% 0.836
30-34 846 33.5% 180 34.3% 0.717
Total 4,121 34.4% 936 35.4%
a p values in all age groups are calculated by the Pearson Chi-Square test.
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rate, this study found comparable rates in women who
received the second generation (8.2%) compared to
women in an age- and ZIP code matched group who re-
ceived the first generation (6.9%), while several other
studies have shown different percentages; it is likely that
these variations are caused by different study popula-
tions, different devices and HPV tests that were used
within studies [11,14,26,27]. The hrHPV positivity rates
in our study are in line with some other reported hrHPV
positivity rates among non-attendees [12,16].
In addition, this study showed that the DNA concentra-
tion of hrHPV positive samples collected with the second
generation was comparable to the mean concentration in
samples obtained with the validated, first generation. This
is interesting, because the lavage volume of the second
generation of the device is smaller (3 ml vs. 5 ml in the
first generation). Since a similar DNA concentration was
measured in samples obtained with this second generation,
these samples still seem appropriate for testing other mo-
lecular (triage) markers, such as methylation markers, on
the self-sampled material, [31] (Hesselink et.al., manuscript
in preparation).
Manufacturing and logistic cost saving advantages of
the second generation device over the first generation
are reported. First, the design of the second generation
device enables high volume production with lower cost
price. Second, the smaller diameter and packaging of the
second generation device allows sending by mail while
the first generation had to be hand-delivered by a post-
man at a higher rate.
The attendance rate in this study was 34.4% with the
first generation and 35.4% with the second generation. A
previous study, in which non-attendees received the first
generation of the Delphi Screener, showed a slightly
lower attendance rate of 27.5% [11]. Two other studies
among non-attendees of the Dutch screening program,
in which women were invited to take a brush-based va-
ginal self-sample, showed a response rate of 34.2% and
30.8%, respectively [10,12]. The attendance rate differs
only slightly in these studies, possibly either due to the
type of self-sampling device or because women had prior
knowledge of self-sampling. Cohort effects, including
seasonal influences, could also play a role. In this study,
a possible effect of cohorts was minimized because the
samples were tested within one cohort.
An important limitation of the current study is that we
did not have histological follow-up of the participating
women yet to compare the clinical accuracy of the differ-
ent versions of the self-sampling device. However, we did
find an equal hrHPV positivity rate and DNA concentra-
tion; therefore, we expect that a comparable percentage of
CIN2+ lesions can be identified independent of the model
that was used, and this study therefore bridges the studies
with the earlier device [11,25] to future studies with the
second generation device. Furthermore, inter-laboratory
heterogeneity could have affected our hrHPV test results,
because two different laboratories performed the HPV
tests in our study. However, we have automatically cor-
rected for this type of bias by correcting for ZIP code by
using a posterior matching procedure, as samples from
women within the same ZIP code were always analyzed in
the same laboratory. The strengths of our study are that
we collected our data in a nested case–control study
within similar age cohorts, and matched for ZIP codes
and age distribution within the cohorts [32].
Conclusions
This study shows that offering a new and improved se-
cond generation of the cervico-vaginal lavage device
results in a comparable hrHPV positivity rate and that
samples contain the same DNA yield as compared to the
first generation of this device. In addition, a comparable
small number of invalid samples were observed taken by
the second generation of the device compared to the
first generation. Therefore, it can be assumed that this
second generation device can be employed with similar
reliability as the first generation device to improve at-
tendance among non-responders in screening programs.
The new design of the device offers cost saving produc-
tion and logistic advantages while it seems to have simi-
lar effect on the participants’ response rate.
Additional files
Additional file 1: User instructions of the first generation lavage
device.
Additional file 2: User instructions of the second generation lavage
device.
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